Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease

Circulation

Volumn 141, Issue 8, 2020, Pages 704-707

  Mazer, C David ^a,c,d,e   Hare, Gregory M T ^a,c,d,e   Connelly, Philip W ^b,e   Gilbert, Richard E ^a,c   Shehata, Nadine ^e,f,g   Quan, Adrian ^a,c   Teoh, Hwee ^a,c   Leiter, Lawrence A ^a,c,d   Zinman, Bernard ^e,h   Jüni, Peter ^a,c,f   Zuo, Fei ^a,c   Mistry, Nikhil ^a,c   Thorpe, Kevin E ^a,c,d   Goldenberg, Ronald M ⁱ   Yan, Andrew T ^a,c   Connelly, Kim A ^a,c,e   Verma, Subodh ^a,c,d,e  

^a University of Toronto   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g Division of Hematology/Oncology   (Canada)

^h MOUNT SINAI HOSPITAL   (Canada)

ⁱ LMC DIABETES AND ENDOCRINOLOGY   (Canada)

Author keywords

empagliflozin; erythrocytes; erythropoietin; iron; sodium glucose transporter 2 inhibitors

Indexed keywords

BENZHYDRYL DERIVATIVE; EMPAGLIFLOZIN; ERYTHROPOIETIN; FERRITIN; GLUCOSIDE;

COMPLICATION; CORONARY ARTERY DISEASE; CYTOLOGY; DRUG EFFECT; ERYTHROCYTE; ERYTHROCYTE COUNT; HEMATOCRIT; HUMAN; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BENZHYDRYL COMPOUNDS; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; ERYTHROCYTE COUNT; ERYTHROCYTES; ERYTHROPOIETIN; FERRITINS; GLUCOSIDES; HEMATOCRIT; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85081101372     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.119.044235     Document Type: Letter

References (5)

1. McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlavek J, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995-2008. doi: 10.1056/NEJMoa1911303
2. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128. doi: 10.1056/NEJMoa1504720
3. Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61:2108-2117. doi: 10.1007/s00125-018-4670-7
4. Sano M, Goto S. Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. Circulation. 2019;139:1985-1987. doi: 10.1161/CIRCULATIONAHA.118.038881
5. Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H, Zuo F, Quan A, Farkouh ME, Fitchett DH, et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial. Circulation. 2019;140:1693-1702. doi: 10.1161/CIRCULATIONAHA. 119.042375